China Hemophilia Treatment Drugs Market is Predicted to Reach USD 2,598.8 Million By 2030 Registering a CAGR of 12.92% | Infinium Global Research

The China Hemophilia Treatment Drugs market was valued at USD 1,110.0 Million in 2022 and is expected to reach USD 2,598.8 Million by 2030 and grow at a CAGR of 12.92% over the forecast period. These treatments are of paramount importance for individuals with hemophilia, a lifelong bleeding disorder that cannot be cured but can be managed through medication. The growth of the market is driven by several key factors, including a rapid increase in life expectancy for hemophiliacs, awareness initiatives by the Chinese government, and advancements in treatment options.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/china/sample-request/14450

Hemophilia A and Hemophilia B are lifelong conditions that result in the inability of blood to clot properly. This condition requires the replacement of missing blood clotting factors, which is achieved through the injection of treatment products. These treatments are instrumental in preventing or reducing the frequency of bleeding episodes in both adults and children with hemophilia.

The rising number of diagnosed hemophilia patients and the use of clotting factor replacement therapies are expected to contribute to the market's growth. As the life expectancy of hemophilia patients has increased over the years, driven by advancements in medical science and safer treatment options, the need for effective treatment drugs has also grown. The lifelong nature of hemophilia ensures continued demand for these treatment drugs in the Chinese market.

Efforts to enhance hemophilia care in China are actively supported by organizations such as the World Federation of Hemophilia (WFH) and the Hemophilia Treatment Centre Collaborative Network of China (HTCCNC). These initiatives are designed to raise awareness, improve public education, and increase access to innovative treatment solutions. Collaboration between companies like Roche and the Chinese government further promotes the diagnosis and treatment of hemophilia.

Despite the significant need for these treatments, the high cost of hemophilia drugs remains a challenge, especially in developing and low-income countries. Hemophilia drugs are among the costliest treatments available, with an average annual cost exceeding USD 2,70,000. This expense is a major barrier to access for many patients, especially when combined with the absence of medical insurance for most individuals.

To address the need for more convenient and less frequent treatments, the market is witnessing the emergence of new drugs, such as emicizumab, which offers extended periods between doses and reduced reliance on regular intravenous infusions. Additionally, longer-lasting clotting factors are on the horizon, reducing the frequency of treatments required. These developments are expected to create better opportunities for the hemophilia treatment drugs market in China.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/china/customization/14450

Table of Content

Chapter 1. Report Overview

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

Chapter 3. Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.2.4. Challenges

3.3. PEST-Analysis

3.4. Porter's Diamond Model for China Hemophilia Treatment Drugs Market

3.5. IGR-Growth Matrix Analysis

3.6. Competitive Landscape in China Hemophilia Treatment Drugs Market

Chapter 4. China Hemophilia Treatment Drugs Market by Drug Class

4.1. Desmopressin

4.2. Antifibrinolytic Agents

4.3. Recombinant Coagulation Factor Concentrates

4.4. Plasma Derived Coagulation Factor Concentrates

4.5. Fibrin Sealents

Chapter 5. China Hemophilia Treatment Drugs Market by Disease Indication

5.1. Hemophilia A

5.2. Hemophilia B

5.3. Others

Chapter 6. China Hemophilia Treatment Drugs Market by Distribution Channel

6.1. E-commerce

6.2. Retail Pharmacies

6.3. Hospital Pharmacies

Chapter 7. Company Profiles

7.1 Competitive Landscape in Hemophilia Treatment Drugs Market

7.1.1 Competitive Landscape

7.2 Company Profiles

7.2.1 Shire

7.2.1.1 Overview

7.2.1.2 Company Snapshot

7.2.1.3 Product Portfolio

7.2.1.4 Recent Developments

7.2.2 F. Hoffmann-La Roche Ltd

7.2.2.1 Overview

7.2.2.2 Company Snapshot

7.2.2.3 Product Portfolio

7.2.2.4 Recent Developments

7.2.3 Novo Nordisk A/S

7.2.3.1 Overview

7.2.3.2 Company Snapshot

7.2.3.3 Product Portfolio

7.2.3.4 Recent Developments

7.2.4 Pfizer, Inc.

7.2.4.1 Overview

7.2.4.2 Company Snapshot

7.2.4.3 Product Portfolio

7.2.4.4 Recent Developments

7.2.5 CSL Behring

7.2.5.1 Overview

7.2.5.2 Company Snapshot

7.2.5.3 Product Portfolio

7.2.5.4 Recent Developments

7.2.6 Bayer AG

7.2.6.1 Overview

7.2.6.2 Company Snapshot

7.2.6.3 Product Portfolio

7.2.6.4 Recent Developments

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/china/enquiry/14450

Reasons to Buy this Report:

=> Comprehensive analysis of regional markets of China hemophilia treatment drugs.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.